7221 Cambridge Research Park
About OptibriumOptibrium provides elegant software solutions for small molecule design, optimisation and data analysis.
CEO: Matthew Segall
CSO: Edmund Champness
Please click here for Optibrium job opportunities.
Tweets by Optibrium
36 articles with Optibrium
Optibrium and North Carolina School of Science and Mathematics mark five years of education collaboration with summer school ‘Computing COVID-19’
Optibrium’s StarDrop™ drug discovery software inspires the next generation of high-school students in their challenge to target COVID-19
4/2/2020Biopharma companies from across the globe provide updates on their pipelines and business practices.
2/21/2020Biopharma and life sciences companies strengthen their leadership teams and board with this week's Movers & Shakers.
Intellegens and Optibrium celebrate success in global challenge to find novel antimalarial compounds
Successful models selected by Open Source Malaria consortium will be progressed through to design novel compounds for synthesis and testing
11/21/2019Companies from across the globe provide updates on their businesses and pipelines.
New extension enables researchers to explore the REAL Space of 11 billion readily accessible compounds directly from StarDrop
10/31/2019Companies from across the globe share updates to their businesses and pipelines.
10/17/2019Companies from across the globe provide business and pipeline updates.
Biotech and pharma companies from across Europe and Asia provide updates on pipeline and business activities.
2/1/2019As January ends, biotech and pharma companies tap new leaders to help drive strategic visions. New hires at Histogen, Indalo, Novartis Oncology, Calico, and more.
Optibrium™, a developer of software for drug discovery, today announced the appointment of Clare Devlin as Financial Director.
Provides students with the opportunity to design new drug-like molecules targeting fibrotic diseases and malaria with cutting-edge drug discovery software
Optibrium, Intellegens and Medicines Discovery Catapult awarded funding to apply machine learning in drug discovery
Optibrium today announced it has appointed Dr. Scott Lyon as Director of Business Development and relocated its Headquarters and R&D facilities, to Cambridge Innovation Park, Cambridge, UK.
Optibrium, Imperial College London And DNDi Collaborate In Drug Development Programme For Neglected Diseases